Piper Jaffray hired Danielle Brill and Joe Catanzaro as senior research analysts in its healthcare equity research group. Covering the biotech sector, Brill and Catanzaro will be based in the firm’s New York office.
“Biopharma is core to our strategy at Piper Jaffray and these hires demonstrate our commitment to providing our institutional and corporate clients with the highest-quality equity research in the industry,” said Michael Cox, co-head of global equities at Piper Jaffray.
Brill has more than 10 years’ experience in the pharmaceutical industry. Prior to joining Piper Jaffray, she was an analyst with Needham & Company covering mid-cap biotech companies. Brill also worked as a clinical pharmacist at Mount Sinai Hospital and Premier and as a senior research technician at New York University and Columbia University Medical Center.
Before joining Piper Jaffray, Catanzaro was a biotech equity research associate at Cowen, where he led the production of Cowen’s biannual Investor’s Guide to Immuno-Oncology.
